P68 Proportion of iNKT cells in pregnant women with preeclampsia: an evaluation in peripheral blood, placenta and umbilical cord blood

2010 ◽  
Vol 1 ◽  
pp. S60
Author(s):  
Leandro DeOliveira ◽  
Marcos Cenedeze ◽  
Rafael Larocca ◽  
Nelson Sass ◽  
Niels Olsen Câmara
2021 ◽  
Vol 12 ◽  
Author(s):  
Sijia Zhao ◽  
Ting Xie ◽  
Li Shen ◽  
Hong Liu ◽  
Liling Wang ◽  
...  

The coronavirus disease 2019 (COVID-19) pandemic has been raging around the world since January 2020. Pregnancy places the women in a unique immune scenario which may allow severe COVID‐19 disease. In this regard, the potential unknown effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on mothers and fetuses have attracted considerable attention. There is no clear consistent evidence of the changes in the immune status of pregnant women after recovery from COVID-19. In this study, we use multiparameter flow cytometry and Luminex assay to determine the immune cell subsets and cytokines, respectively, in the peripheral blood and umbilical cord blood from pregnant women recovering from COVID-19 about 3 months (n=5). Our results showed decreased percentages of Tc2, Tfh17, memory B cells, virus-specific NK cells, and increased percentages of naive B cells in the peripheral blood. Serum levels of IL-1ra and MCP-1 showed a decreased tendency in late recovery stage (LRS) patients. Meanwhile, there was no significant difference in immune cell subsets in the umbilical cord blood. The placentas from LRS patients showed increased CD68+ macrophages infiltration and mild hypoxic features. The inflammatory damage of the placenta may be related to the antiviral response. Since the receptors, ACE2 and TMPRSS2, utilized by SARS-CoV-2 are not co-expressed in the placenta, so it is extremely rare for SARS-CoV-2 to cause infection through this route and the impact on the fetus is negligible.


2008 ◽  
Vol 215 (4) ◽  
pp. 363-371 ◽  
Author(s):  
Darko Grujicic ◽  
Olivera Miloševic-Djordjevic ◽  
Slobodan Arsenijevic ◽  
Dragoslav Marinkovic

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 1062
Author(s):  
M. Barbosa ◽  
V. Molla ◽  
A. Mendroni Junior ◽  
M. Goncalves ◽  
E. Kimura ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
L. Herrera ◽  
S. Santos ◽  
M. A. Vesga ◽  
J. Anguita ◽  
I. Martin-Ruiz ◽  
...  

AbstractAmong hematological cancers, Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) are the most common leukemia in children and elderly people respectively. Some patients do not respond to chemotherapy treatments and it is necessary to complement it with immunotherapy-based treatments such as chimeric antigen receptor (CAR) therapy, which is one of the newest and more effective treatments against these cancers and B-cell lymphoma. Although complete remission results are promising, CAR T cell therapy presents still some risks for the patients, including cytokine release syndrome (CRS) and neurotoxicity. We proposed a different immune cell source for CAR therapy that might prevent these side effects while efficiently targeting malignant cells. NK cells from different sources are a promising vehicle for CAR therapy, as they do not cause graft versus host disease (GvHD) in allogenic therapies and they are prompt to attack cancer cells without prior sensitization. We studied the efficacy of NK cells from adult peripheral blood (AB) and umbilical cord blood (CB) against different target cells in order to determine the best source for CAR therapy. AB CAR-NK cells are slightly better at killing CD19 presenting target cells and CB NK cells are easier to stimulate and they have more stable number from donor to donor. We conclude that CAR-NK cells from both sources have their advantages to be an alternative and safer candidate for CAR therapy.


1989 ◽  
Vol 27 (3) ◽  
pp. 137-142 ◽  
Author(s):  
Ralph J. Lellé ◽  
Eberhard Henkel ◽  
Dieter Leinemann ◽  
Klaus Goeschen

2007 ◽  
Vol 29 (6) ◽  
pp. 388-392 ◽  
Author(s):  
Javier Garc??a-Castro ◽  
Antonio Balas ◽  
Manuel Ram??rez ◽  
Antonio P??rez-Mart??nez ◽  
Luis Madero ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document